COMPOUNDS AND METHODS OF TREATING DIABETES

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of...

Full description

Saved in:
Bibliographic Details
Main Authors CHAKRAVARTY SARVVAJIT, PROTTER ANDREW ASHER
Format Patent
LanguageEnglish
Published 14.08.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
AbstractList Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
Author CHAKRAVARTY SARVVAJIT
PROTTER ANDREW ASHER
Author_xml – fullname: CHAKRAVARTY SARVVAJIT
– fullname: PROTTER ANDREW ASHER
BookMark eNrjYmDJy89L5WTQcvb3DfAP9XMJVnD0c1HwdQ3x8Aey_d0UQoJcHUM8_dwVXDwdnVxDXIN5GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8aLCRgaGJkZGFsamxo6ExcaoAy7MnMg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2014228353A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2014228353A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:05:42 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2014228353A13
Notes Application Number: US201214000197
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140814&DB=EPODOC&CC=US&NR=2014228353A1
ParticipantIDs epo_espacenet_US2014228353A1
PublicationCentury 2000
PublicationDate 20140814
PublicationDateYYYYMMDD 2014-08-14
PublicationDate_xml – month: 08
  year: 2014
  text: 20140814
  day: 14
PublicationDecade 2010
PublicationYear 2014
RelatedCompanies CHAKRAVARTY SARVVAJIT
PROTTER ANDREW ASHER
MEDIVATION TECHNOLOGIES, INC
RelatedCompanies_xml – name: CHAKRAVARTY SARVVAJIT
– name: PROTTER ANDREW ASHER
– name: MEDIVATION TECHNOLOGIES, INC
Score 2.9521527
Snippet Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title COMPOUNDS AND METHODS OF TREATING DIABETES
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140814&DB=EPODOC&locale=&CC=US&NR=2014228353A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlILSB6HY2qbdHoq0TWon9IM1lb2NtU1AkDlcxX_fpHS6p71dcnD5gMvlLve7ANxz22Emk7CPJ6Zrll2W2sLkpcaRU49rxpFuSjRynNhRYb3O0KwHHxssTFsn9Kctjig0qhL63rTn9eo_iIXb3Mr1Y_kuuj6fQ-pitfOOhbcwMiwV-y7JUpwGahC4Ra4m05YnK70g0xO-0p64SDsyAYy8-RKXsto2KuEx7GdC3rI5gR5bDuAw2Py9NoCDuHvyFmSnfetTeAjSOEuLBOeKl2AlJjRKBZ2GCp0Sj06SFwVPPJ9Qkp_BXUhoEGli0PnfGudFvj1D8xz6wvtnF6AsmM0Mg-t6xU2rROORPqr1qnJk2XWOkH0Jw12Srnazr-FINmWQ1LCG0G--vtmNsLJNedtuzi9g4HuE
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQWlD0KxXZuueyjSNamdru1YU9nbWLsEBJnDVfz3TUqne9rbkYPLB1wud8nvF4B7bveYySTso8t0zbLzXJubPNc46i36C8aRbko0chTbYWa9TNG0AR8bLEzFE_pTkSMKjyqEv5fVfr36L2Lh6m3l-jF_F02fTwF1sVpnxyJbcAxLxQOXjBOc-Krvu1mqxpNKJ5lekOmJXGlPHLIdybRP3gYSl7LaDirBEeyPhb1leQwNtmxDy9_8vdaGg6i-8hZi7X3rE3jwk2icZDFOFS_GSkRomAg5CRQ6IR4dxs8KHnoDQkl6CncBoX6oiU5nf3OcZen2CM0zaIrsn52DMmc2Mwyu6wU3rRz1Hd1Z6EXRk7TrHCH7Ajq7LF3uVt9CK6TRaDYaxq9XcChVsmBqWB1oll_f7FpE3DK_qRbqF1M-fnQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMPOUNDS+AND+METHODS+OF+TREATING+DIABETES&rft.inventor=CHAKRAVARTY+SARVVAJIT&rft.inventor=PROTTER+ANDREW+ASHER&rft.date=2014-08-14&rft.externalDBID=A1&rft.externalDocID=US2014228353A1